Lexeo Therapeutics’ (LXEO) Buy Rating Reiterated at Chardan Capital

Chardan Capital reissued their buy rating on shares of Lexeo Therapeutics (NASDAQ:LXEO) in a report issued on Tuesday,Benzinga reports. They currently have a $25.00 price objective on the stock.

A number of other research firms also recently issued reports on LXEO. Royal Bank of Canada reiterated an “outperform” rating and issued a $24.00 price objective on shares of Lexeo Therapeutics in a report on Tuesday, January 21st. Leerink Partners lowered their price target on shares of Lexeo Therapeutics from $19.00 to $18.00 and set an “outperform” rating for the company in a research report on Monday. Five investment analysts have rated the stock with a buy rating and one has issued a strong buy rating to the company’s stock. Based on data from MarketBeat, the stock presently has a consensus rating of “Buy” and a consensus target price of $22.80.

Lexeo Therapeutics Trading Up 3.0 %

NASDAQ:LXEO opened at $4.11 on Tuesday. The company has a 50-day moving average price of $4.07 and a 200-day moving average price of $6.63. The stock has a market cap of $135.90 million, a price-to-earnings ratio of -1.30 and a beta of 3.85. The company has a current ratio of 5.95, a quick ratio of 5.95 and a debt-to-equity ratio of 0.01. Lexeo Therapeutics has a 12 month low of $2.32 and a 12 month high of $19.50.

Lexeo Therapeutics (NASDAQ:LXEO) last issued its quarterly earnings data on Monday, March 24th. The company reported ($0.78) EPS for the quarter, topping the consensus estimate of ($0.87) by $0.09. Equities analysts predict that Lexeo Therapeutics will post -3.14 EPS for the current year.

Hedge Funds Weigh In On Lexeo Therapeutics

Several large investors have recently modified their holdings of the stock. Janus Henderson Group PLC grew its holdings in shares of Lexeo Therapeutics by 15.3% during the fourth quarter. Janus Henderson Group PLC now owns 4,339,254 shares of the company’s stock valued at $28,508,000 after buying an additional 576,059 shares during the last quarter. Frazier Life Sciences Management L.P. purchased a new stake in Lexeo Therapeutics during the 3rd quarter valued at $11,307,000. Vestal Point Capital LP increased its holdings in shares of Lexeo Therapeutics by 41.2% in the 4th quarter. Vestal Point Capital LP now owns 1,200,000 shares of the company’s stock worth $7,896,000 after purchasing an additional 350,000 shares in the last quarter. Woodline Partners LP raised its stake in shares of Lexeo Therapeutics by 0.8% in the fourth quarter. Woodline Partners LP now owns 858,691 shares of the company’s stock worth $5,650,000 after purchasing an additional 6,730 shares during the last quarter. Finally, Verition Fund Management LLC lifted its holdings in shares of Lexeo Therapeutics by 84.5% during the third quarter. Verition Fund Management LLC now owns 777,320 shares of the company’s stock valued at $7,027,000 after purchasing an additional 355,928 shares in the last quarter. Hedge funds and other institutional investors own 60.67% of the company’s stock.

About Lexeo Therapeutics

Lexeo Therapeutics, Inc operates as a clinical stage genetic medicine company that focuses on hereditary and acquired diseases. The company develops LX2006, which is an AAVrh10-based gene therapy candidate for the treatment of Friedreich's ataxia (FA) cardiomyopathy; LX2020, an AAVrh10-based gene therapy candidate for the treatment of plakophilin-2 arrhythmogenic cardiomyopathy; LX2021, a gene therapy candidate for the treatment of DSP cardiomyopathy associated with it; and LX2022, a gene therapy candidate for the treatment of hypertrophic cardiomyopathy, or HCM caused by TNNI3 gene.